

Datasheet: MCA2537T

| | |
|----------------------|-----------------------|
| Description: | MOUSE ANTI HUMAN CD16 |
| Specificity: | CD16 |
| Other names: | FcRIII |
| Format: | Purified |
| Product Type: | Monoclonal Antibody |
| Clone: | DJ130c |
| Isotype: | IgG1 |
| Quantity: | 25 µg |

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

| | Yes | No | Not Determined | Suggested Dilution |
|--------------------------------|-----|----|----------------|--------------------|
| Flow Cytometry | ▪ | | | 1/20 - 1/200 |
| Immunohistology - Frozen | ▪ | | | |
| Immunohistology - Paraffin (1) | ▪ | | | |
| ELISA | | | ▪ | |
| Immunoprecipitation | | | ▪ | |
| Western Blotting | | | ▪ | |

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

(1) This product requires antigen retrieval using heat treatment prior to staining of paraffin sections. Sodium citrate buffer pH 6.0 is recommended for this purpose.

| | |
|---------------------------------|---|
| Target Species | Human |
| Species Cross Reactivity | <p>Reacts with: Macaque</p> <p>N.B. Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.</p> |
| Product Form | Purified IgG - liquid |

| | |
|--|---|
| Preparation | Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant |
| Buffer Solution | Phosphate buffered saline |
| Preservative Stabilisers | 0.09% Sodium Azide (NaN ₃) |
| Carrier Free | Yes |
| Approx. Protein Concentrations | IgG concentration 1.0mg/ml |
| External Database Links | <p>UniProt:</p> <p>P08637 Related reagents</p> <p>O75015 Related reagents</p> <p>Entrez Gene:</p> <p>2214 FCGR3A Related reagents</p> <p>2215 FCGR3B Related reagents</p> |
| Synonyms | CD16A, CD16B, FCG3, FCGR3, IGFR3 |
| RRID | AB_2104006 |
| Specificity | <p>Mouse anti Human CD16 antibody, clone DJ130c recognizes human CD16, also known as Low affinity immunoglobulin gamma Fc region receptor III-A or Fc-gamma RIIIa. CD16a is a 254 amino acid ~50-65 kDa single pass type 1 transmembrane glycoprotein bearing two Ig-like C2 type domains. CD16 exists as a transmembranous form (Fc gammaRIIIA, or CD16A) and a glycosyl phosphatidylinositol (GPI) anchored form, Fc gammaRIIIB, or CD16B (Scallon et al. 1989). CD16A is expressed by NK cells, some T cells, and macrophages, whereas CD16B is primarily expressed by granulocytes (Ravetch and Perussia 1989). In addition, CD16B exists as two allelic variants NA1 and NA2 . DJ130c recognizes all polymorphonuclear cells irrespective of their NA phenotype.</p> <p>Mouse anti Human CD16 antibody, clone DJ130c recognizes an epitope in the first membrane-distal domain of CD16, recognizes both CD16a and CD16b and has been demonstrated to cross-react with CD16 from rhesus macaques, <i>Macaca mulatta</i> (Xu et al. 2012)</p> |
| Flow Cytometry | Use 10ul of the suggested working dilution to label 1x10 ⁶ cells in 100ul. |
| Histology Positive Control Tissue | Human tonsil |
| References | 1. Schmidt, R.E. (1993) CD16 cluster workshop report. In Leucocyte Typing V: White cell differentiation antigens, Vol.1. Edited by Schlossman, S.F. <i>et al.</i> Oxford University Press. |

p805 – 806.

2. Kakko, T. *et al.* (2011) Inflammatory effects of blood leukocytes: association with vascular function in neuropeptide Y proline 7-genotyped type 2 diabetes patients. [Diab Vasc Dis Res. 8: 221-8.](#)
3. Shantsila, E. *et al.* (2012) Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways. [Thromb Haemost. 108: 32-40.](#)
4. Shantsila, E. *et al.* (2011) Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. [J Thromb Haemost. 9: 1056-66.](#)
5. Tapp, L.D. *et al.* (2012) The CD14⁺⁺CD16⁺ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. [J Thromb Haemost. 10: 1231-41.](#)
6. Ambarus, C.A. *et al.* (2012) Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitis. [Arthritis Res Ther. 14: R74.](#)
7. Ambarus, C.A. *et al.* (2012) Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. [J Immunol Methods. 375: 196-206.](#)
8. Ambarus, C.A. *et al.* (2012) Soluble immune complexes shift the TLR-induced cytokine production of distinct polarized human macrophage subsets towards IL-10. [PLoS One. 7: e35994.](#)
9. Shantsila, E. *et al.* (2012) The effects of exercise and diurnal variation on monocyte subsets and monocyte-platelet aggregates. [Eur J Clin Invest. 42: 832-9.](#)
10. Chehadeh, W. *et al.* (2009) Antibody-mediated opsonization of red blood cells in parvovirus B19 infection. [Virology. 390: 56-63.](#)
11. Wrigley, B.J. *et al.* (2013) Increased formation of monocyte-platelet aggregates in ischemic heart failure. [Circ Heart Fail. 6: 127-35.](#)
12. Jaipersad, A.S. *et al.* (2014) Expression of monocyte subsets and angiogenic markers in relation to carotid plaque neovascularization in patients with pre-existing coronary artery disease and carotid stenosis. [Ann Med. 11: 1-9.](#)
13. Shantsila, E. *et al.* (2015) Free Light Chains in patients with acute coronary syndromes: Relationships to inflammation and renal function. [Int J Cardiol. 185: 322-7.](#)
14. Wrigley, B.J. *et al.* (2013) Increased formation of monocyte-platelet aggregates in ischemic heart failure. [Circ Heart Fail. 6 \(1\): 127-35.](#)
15. Romee R *et al.* (2013) NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). [Blood. 121 \(18\): 3599-608.](#)
16. Sousa, S. *et al.* (2015) Human breast cancer cells educate macrophages toward the M2 activation status. [Breast Cancer Res. 17: 101.](#)
17. Shantsila, E. *et al.* (2019) Mon2 predicts poor outcome in ST-elevation myocardial infarction. [J Intern Med. 285 \(3\): 301-16.](#)
18. Brown, R.A. *et al.* (2018) Impact of Mon2 monocyte-platelet aggregates on human coronary artery disease. [Eur J Clin Invest. 48 \(5\): e12911.](#)
19. Nakajima-Kato, Y. *et al.* (2023) A novel monoclonal antibody with improved FcγR blocking ability demonstrated non-inferior efficacy compared to IVIG in cynomolgus monkey ITP model at considerably lower dose. [Clin Exp Immunol. 211 \(1\): 23-30.](#)

Storage

This product is shipped at ambient temperature. It is recommended to aliquot and store at

-20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

| | |
|------------------|---------------------------------|
| Guarantee | 12 months from date of despatch |
|------------------|---------------------------------|

| | |
|--------------------------------------|--|
| Health And Safety Information | Material Safety Datasheet documentation #10040 available at: https://www.bio-rad-antibodies.com/SDS/MCA2537T 10040 |
|--------------------------------------|--|

| | |
|-------------------|----------------------------|
| Regulatory | For research purposes only |
|-------------------|----------------------------|

Related Products

Recommended Secondary Antibodies

| | |
|---|---|
| Rabbit Anti Mouse IgG (STAR12...) | RPE |
| Goat Anti Mouse IgG IgA IgM (STAR87...) | HRP |
| Goat Anti Mouse IgG (STAR76...) | RPE |
| Rabbit Anti Mouse IgG (STAR13...) | HRP |
| Goat Anti Mouse IgG (STAR70...) | FITC |
| Goat Anti Mouse IgG (H/L) (STAR117...) | Alk. Phos. , DyLight@488 , DyLight@550 , DyLight@650 , DyLight@680 , DyLight@800 , FITC , HRP |
| Rabbit Anti Mouse IgG (STAR9...) | FITC |
| Goat Anti Mouse IgG (STAR77...) | HRP |
| Goat Anti Mouse IgG (Fc) (STAR120...) | FITC , HRP |

Recommended Negative Controls

[MOUSE IgG1 NEGATIVE CONTROL \(MCA928\)](#)

| | | | | | |
|----------------------------------|---|------------------|---|---------------|---|
| North & South America | Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com | Worldwide | Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com | Europe | Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com |
|----------------------------------|---|------------------|---|---------------|---|

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M383938:210513'

Printed on 18 Jan 2024